2023年9月20日,和誉医药(港交所代码:02256)宣布,公司两项临床前研究结果成功入选10月于美国波士顿举行的第35届国际分子靶标与癌症治疗大会(EORTC-NCI-AACR conference, 以下简称ENA大会)。这两项研究成果分别展示了和誉医药在研管线中新一代PRMT5*MTA抑制剂和可入脑PD-L1小分子抑制剂的最新临床前研究进展。作为...
Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and C...
Cybrexa Therapeutics today announced it will present data findings on its preclinical candidate, CBX-15 (alphalex™-MMAE) for the treatment of triple negative breast cancer in a poster session at th...
Abbisko is going to disclose two pre-clinical research results at the 35th EORTC-NCI-AACR Conference Sep 20,2023 By Abbisko Back Abstract title:Discovery and characterization of an MTA-cooperative and brain-penetrant PRMT5 inhibitor Poster number:C130...
2022年第34届EORTC-NCI-AACR分子靶标与癌症治疗学研讨会(国际会议)将于2022年10月26日至28日在西班牙巴塞罗那举行,会议由美国癌症研究协会(AACR)、美国国家癌症研究所(NCI)和欧洲癌症研究与治疗组织(EORTC)共同主办,EORTC-NCI-AACR研讨会将汇集来自世界各地的学者、科学家和制药企业代表,共同讨论药物开发、目标选择及...
NCI-EORTC-AACR - 11th Symposium on New Drugs in Cancer Therapy: Selected symposia and poster sessionsD GrayIdrugs
(PD) biomarker, while revealing potential novel PD markers, and identified an initial novel patient selection gene expression signature that will, in part, be evaluated in its planned Phase 1/2 study. The data are being presented at the 34th EORTC-NCI-AACR (ENA 2022) Symposium on Molecular ...
data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class, highly selective SMARCA2 degrader designed to treat cancer patients with a SMARCA4 mutation. The data were presented at a plenary session of the 36thAnnual EORTC-NCI-AACR Symposium in Barcelona, ...
EORTC-NCI-AACR (ENA)-Symposium 2024 vom 23. bis 25. Oktober in Barcelona, Spanien, vorgestellt werden. „Während unsere präzisionsentwickelten LSD1- und MALT1-Inhibitoren weiter in Richtung des klinischen Stadiums voranschreiten, freuen wir uns, neue präklinische Daten aus beiden ...
Study: Extend Quality Assessment to Phase I Abstracts: Poster Study at EORTC-NCI-AACR Meeting Gives Suggested Guidelinesdoi:10.1097/01.COT.0000343990.74265.d4An abstract is unavailable.Lindsey, HeatherOncology Times